Education
About Us
Working with TipRanks
Follow Us
Galecto (GLTO)
NASDAQ:GLTO
GLTO Stock Chart & Stats
$24.98
-$0.21(-3.82%)
At close: 4:00 PM EST
$24.98
-$0.21(-3.82%)
Day’s Range― - ―
52-Week Range$2.01 - $38.33
Previous CloseN/A
Volume2.41K
Average Volume (3M)5.26M
Market Cap
$39.89M
Enterprise Value-$4.29M
Total Cash (Recent Filing)$7.61M
Total Debt (Recent Filing)$1.41M
Price to Earnings (P/E)―
Beta0.12
Next Earnings
Mar 30, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.36
Shares Outstanding1,597,321
10 Day Avg. Volume9,383,356
30 Day Avg. Volume5,257,093
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.34
Price to Sales (P/S)0.00
P/FCF Ratio-0.29
Enterprise Value/Market Cap-0.11
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit857.02
Enterprise Value/Ebitda0.27
Forecast
1Y Price Target
$41.00Price Target Upside64.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
AcquisitionAnalyst highlights that acquiring Damora brings DMR-001 into the pipeline and accelerates development of therapies targeting mutant calreticulin, strengthening the company's clinical portfolio.
Commercial Formulation AdvantageAnalyst notes that a subcutaneous formulation for DMR-001 could provide dosing convenience relative to intravenous-only rivals, supporting patient adoption and market share growth even as a later entrant.
Therapeutic DifferentiationAnalyst points out that DMR-001's higher potency and targeted mechanism could position it as a best-in-class therapy for patients with mutant calreticulin, offering potential clinical advantages over existing treatments.
Bears Say
Competitive First-mover RiskAnalyst warns that a first-mover competitor with demonstrated clinical progress targeting the same mutation could challenge market entry and limit adoption of new entrants.
Galecto News
GLTO FAQ
What was Galecto’s price range in the past 12 months?
Galecto lowest stock price was $2.01 and its highest was $38.33 in the past 12 months.
What is Galecto’s market cap?
Galecto’s market cap is $39.89M.
When is Galecto’s upcoming earnings report date?
Galecto’s upcoming earnings report date is Mar 30, 2026 which is in 70 days.
How were Galecto’s earnings last quarter?
Galecto released its earnings results on Nov 06, 2025. The company reported -$2.36 earnings per share for the quarter, missing the consensus estimate of N/A by -$2.36.
Is Galecto overvalued?
According to Wall Street analysts Galecto’s price is currently Undervalued.
Does Galecto pay dividends?
Galecto does not currently pay dividends.
What is Galecto’s EPS estimate?
Galecto’s EPS estimate is -0.14.
How many shares outstanding does Galecto have?
Galecto has 1,597,321 shares outstanding.
What happened to Galecto’s price movement after its last earnings report?
Galecto reported an EPS of -$2.36 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -14.948%.
Which hedge fund is a major shareholder of Galecto?
Currently, no hedge funds are holding shares in GLTO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Galecto Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$41.00 (64.13% Upside)
$41.00 (64.13% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
42.34%
12-Months-Change
Fundamentals
Return on Equity
-114.81%
Trailing 12-Months
Asset Growth
-49.84%
Trailing 12-Months
Company Description
Galecto
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
GLTO Stock 12 Month Forecast
Average Price Target
$41.00
▲(64.13% Upside)
Technical Analysis
Matinas BioPharma
―
Quoin Pharmaceuticals
―
Silo Pharma
―
GRI Bio
―
Conduit Pharmaceuticals
―
Ownership Overview
18.85% Insiders
1.06% Mutual Funds
7.93% Other Institutional Investors
71.47% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---